Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

Ratios

vs
industry
vs
history
P/E(ttm) 14.76
PID's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 14.76 )
Ranked among companies with meaningful P/E(ttm) only.
PID' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 14.76
PE(NRI) 14.76
PID's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 14.76 )
Ranked among companies with meaningful PE(NRI) only.
PID' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 14.76
P/B 1.23
PID's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 1.23 )
Ranked among companies with meaningful P/B only.
PID' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 1.23

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.67
PID's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 3.67 )
Ranked among companies with meaningful Dividend Yield only.
PID' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 3.67

More Statistics

Short Percentage of Float0.00%
52-Week Range $11.44 - 18.41
Shares Outstanding(Mil)81500000.00
» More Articles for PID

Headlines

Articles On GuruFocus.com
Ben Graham's Congressional Hearing Apr 30 2016 
What Investors Need to Know About GM’s 1st-Quarter Earnings Apr 30 2016 
Investors Should Consider Snyder's-Lance Apr 30 2016 
U.S. Market Indexes Close Lower for the Week Apr 30 2016 
Baron Real Estate Fund's 1st-Quarter Letter Part One Apr 30 2016 
Carl Icahn Interview With CNBC Apr 30 2016 
Mattel Is a Definite Short Right Now Apr 29 2016 
Here Are PayPal’s Growth Drivers for the Next Decade Apr 29 2016 
Why Icahn Sold Apple Apr 29 2016 
Apple Is Facing a Big Problem Apr 29 2016 

More From Other Websites
What Analysts Expect for CF Industries’ Gross Margins May 01 2016
Will Agrium Report a Dip in Sales in 1Q16? Apr 27 2016
Novartis’s Pharmaceutical Revenue Reported Growth in 1Q16 Apr 27 2016
PID: An ETF Performance Case Study Apr 20 2016
Oil Prices Are Tethered to Loads Of Overseas Stock ETFs, Too Apr 19 2016
Victoza to Fuel Growth for Novo Nordisk Apr 15 2016
Inside WisdomTree's New Dividend Growth ETF Apr 15 2016
Analyzing Novo’s Haemophilia and Growth Hormone Portfolio Apr 13 2016
How Is Novo Nordisk Doing in the Diabetes Space? Apr 12 2016
How Will Teva Boost Operating Margins for Its Generic Business? Mar 30 2016
What Does Novartis Expect for Its Pharmaceuticals Segment in 1Q16? Mar 29 2016
What Do Analysts Estimate for Novartis? Mar 29 2016
Understanding GlaxoSmithKline’s Transformation for Growth Mar 15 2016
Assessing GlaxoSmithKline’s Vaccines Business Mar 15 2016
Rare Disease Portfolio Helped Sanofi to Offset Falling Diabetes Sales Mar 15 2016
Analyzing Sanofi’s Performance Based on Its EV-to-EBITDA Mar 07 2016
Sizing up GlaxoSmithKline’s Consumer Healthcare Segment Mar 04 2016
The Declining Revenues of GlaxoSmithKline’s Pharmaceutical Segment Mar 04 2016
Anlyzing Vodafone’s Value Proposition in the Global Telecom Market Feb 19 2016
How Tresiba and Xultophy Will Drive Novo’s Performance Feb 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK